| Title |
Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials
|
|---|---|
| Published in |
Irish Journal of Medical Science, February 2016
|
| DOI | 10.1007/s11845-016-1414-x |
| Pubmed ID | |
| Authors |
B. Zhu, L. Zhang, Y. Y. Fan, L. Wang, X. G. Li, T. Liu, Y. S. Cao, Z. G. Zhao |
| Abstract |
Metformin is widely used in treatment of type 2 diabetes. However, whether it is safe for use in pregnancy is controversial. A search for relevant studies were performed using PubMed (1948-2014), Embase (1974-2014), the Web of knowledge (1950-2014), and the Cochrane database, included all randomized control trials published in English. Eight RCTs (1712 patients with gestational diabetes mellitus) were retrieved; of those 853 patients were given metformin, and 859 patients were given insulin. Our results showed that metformin does not increase risk of prematurity (RR = 1.26; 95 % CI [0.89, 1.79], P = 0.19). In addition, metformin can either decrease the total weight gain [MD = -1.49, 95 % CI (-2.66, -0.31), P = 0.01] or weight gain after randomization [MD = -1.23, 95 % CI (-1.75, -0.71), P < 0.00001]. No significant differences were observed in patients with pre-eclampsia [RR = 0.82, 95 % CI (0.56, 1.2), P = 0.32] or caesarean section [RR = 0.93, 95 % CI (0.75, 1.16), P = 0.53]. Use of metformin also significantly decreased the risk of neonatal hypoglycemia [RR = 0.58, 95 % CI (0.43, 0.78), P = 0.0003] and admission rates to neonatal intensive care units [RR = 0.74, 95 % CI (0.61, 0.89), P = 0.002]. No other adverse effects were observed, such as hyperbilirubinaemia [RR = 0.83, 95 % CI (0.64, 1.08), P = 0.16], large for gestational age [RR = 0.85, 95 % CI (0.68, 1.05), P = 0.14], small for gestational age [RR = 0.92, 95 % CI (0.61, 1.39), P = 0.69], macrosomia [RR = 0.75, 95 % CI (0.54, 1.03), P = 0.07] or respiratory distress syndrome [RR = 0.88, 95 % CI (0.55, 1.41), P = 0.6]. Metformin may be beneficial in treating gestational diabetes. However, even more studies are needed to provide more evidence for the future use of metformin. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 118 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 14% |
| Other | 15 | 13% |
| Researcher | 13 | 11% |
| Student > Postgraduate | 12 | 10% |
| Student > Bachelor | 11 | 9% |
| Other | 23 | 19% |
| Unknown | 28 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 42% |
| Nursing and Health Professions | 8 | 7% |
| Agricultural and Biological Sciences | 5 | 4% |
| Unspecified | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 16 | 14% |
| Unknown | 30 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2016.
All research outputs
#16,337,555
of 24,074,720 outputs
Outputs from Irish Journal of Medical Science
#832
of 1,482 outputs
Outputs of similar age
#244,113
of 408,287 outputs
Outputs of similar age from Irish Journal of Medical Science
#13
of 34 outputs
Altmetric has tracked 24,074,720 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,482 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 408,287 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.